RALEIGH, N.C., Nov. 10, 2009 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), a biopharmaceutical development company, presented preclinical data for DB959, its lead compound for Type 2 Diabetes (T2D), that demonstrated superior performance to comparator drugs at the Cambridge Healthtech Institute’s Conference, “Targeting Diabetes with Novel Therapeutics” held November 3 - 4, 2009 in Boston, MA. Mary Kay Delmedico, Ph.D., DARA’s Project Leader/Program Manager reviewed DB959’s favorable pharmacological and safety profile as a unique first-in-class peroxisome proliferator-activated receptor (PPAR)-delta/gamma agonist without PPAR-alpha activity.
